| Document |
Document Title |
|
JP2023084709A |
To provide a compound having a histamine H4 receptor-regulating effect and being useful for treating a disease caused by the histamine H4 receptor and a pharmaceutically acceptable salt thereof, and a medical composition containing the s...
|
|
JP2023525035A |
The present disclosure provides compounds of Formula I that are useful for activating trigger receptor 2 (TREM2) expressed on myeloid cells. The disclosure also provides pharmaceutical compositions comprising the compounds, uses of the c...
|
|
JP7286631B2 |
The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid,...
|
|
JP7285785B2 |
The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solva...
|
|
JP2023515629A |
The present invention provides CDK2/4/6 inhibitors, pharmaceutical compositions thereof and methods of use thereof.
|
|
JP2023514328A |
The present invention provides a novel formula (1) [In the formula, X, Y, R1, R2, R3, R4and R5is as defined herein. ] or salts thereof and for use in the treatment, prevention, alleviation, control or risk reduction of disorders associat...
|
|
JP2023507516A |
The present invention provides compounds represented by formula (I) below: A[B-(C)v]w (I) where A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. There...
|
|
JP2023016976A |
To provide a method for treating disease.The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions compri...
|
|
JP7204662B2 |
The present invention is directed towards isomerically pure 18F-labelled (6S)- or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycl...
|
|
JP2023002532A |
To provide crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F and G, and combinations thereof, and crystalline polymorphs of salts of sepiapterin, and to disclose pharmaceutical compositions containing o...
|
|
JP7192139B2 |
The present disclosure provides a compound of Formula (I):or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...
|
|
JP7169292B2 |
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising(i) 5-methyl-(6S)-tetrahydrofolic acid,(ii) sodium and(iii) an organic base having a pKa value from 6 to 11;wherein the molar ratio of ...
|
|
JP2022546055A |
The present disclosure provides compounds and corresponding drug conjugates having the structure shown in formula (101), which are capable of specifically targeting cells, exhibiting low toxicity, and excellent delivery efficiency. have ...
|
|
JP2022545102A |
The present invention relates to a method for producing L-erythro-biopterin compounds. Here, the L-erythro-biopterin compound has a structure represented by formula (I), and the L-erythro-biopterin compound represented by (I) is mainly r...
|
|
JP7148533B2 |
Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical composition...
|
|
JP7148532B2 |
Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular ...
|
|
JP2022519936A |
In immunoglobulin light chain amyloidosis (AL), a unique antibody light chain (LC) protein secreted by monoclonal plasma cells in each patient misfolds and / or aggregates, a process that leads to organ degeneration. be. Amyloid formatio...
|
|
JP2022517866A |
The present invention discloses an AKT inhibitor, specifically a compound of formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a method for preparing the same, as well as its use for preventi...
|
|
JP2022517189A |
Pyrido-pyrimidinone and pteridinone compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, as well as substituents and structural features are described herein. Also described are pharmaceutical composition...
|
|
JP2022024035A |
To provide highly stable hemisulfate of 5,10-methylene-(6R)-tetrahydrofolic acid.A lyophilizate is prepared by the steps of i) dissolving hemisulfate of 5,10-methylene-(6R)-tetrahydrofolic acid in water; ii) freezing the water; and iii) ...
|
|
JP2022506246A |
The present invention relates to a crystalline folate. This folate salt consists of folate anions and organic cations. This folic acid anion is 5-methyl- (6S) -tetrahydrofolic acid, and this organic cation consists of a group consisting ...
|
|
JP2022000424A |
To provide: antibodies that interact with an osteoprotegerin ligand (OPGL), which is a member of the TNF family of cytokines and promotes formation of osteoclasts through binding to the receptor activator of NF-kB; and methods of treatin...
|
|
JP2021530466A |
The present invention is a crystalline salt of 5-methyl- (6S) -tetrahydrofolic acid and L-isoleucine ethyl ester in which the molar ratio of 5-methyl- (6S) -tetrahydrofolic acid to L-isoleucine ethyl ester is 1: 1. The present invention ...
|
|
JP2021529802A |
In the present invention, the molar ratio of 5-methyl- (6S) -tetrahydrofolic acid L-leucine ethyl ester (where 5-methyl- (6S) -tetrahydrofolic acid and L-leucine ethyl ester is 1: 0.3 to 1: With respect to crystalline salts containing 3....
|
|
JP2021529206A |
The present invention relates to the molar ratio of 5-methyl- (6S) -tetrahydrofolic acid and 4- (2-hydroxyethyl) -morpholine (5-methyl- (6S) -tetrahydrofolic acid to 4- (2-hydroxyethyl) -morpholine. Contains 1: 0.3 to 1: 2.0 (mol / mol))...
|
|
JP2021527031A |
The present invention relates to novel pharmaceutical salts and / or co-crystals of sepiapterin that exhibit improved properties. In particular, the present invention relates to salts of sepiapterin with improved stability. The present i...
|
|
JP2021522237A |
The present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cell proliferation disorders (eg, cancer). The compounds o...
|
|
JP2021073200A |
To provide novel carrier compositions for efficiently delivering a therapeutic agent, diagnostic agent, or targeting agent to a therapeutic site, in the treatment of diseases such as cancer, or in vivo diagnosis.Provided is a carrier com...
|
|
JP6809781B2 |
To provide a compound having nitrogen monooxide production promoting effect, blood vessel protecting effect, trace quantity albumin urine suppressing effect or the like superior to tetrahydrobiopterin (BH4), for compensating reduction of...
|
|
JP6778259B2 |
The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention al...
|
|
JP6764501B2 |
The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chem...
|
|
JP6747642B2 |
The present specification provides a benzocarbazole-based compound of Chemical Formula 1, and an organic light emitting device comprising the same.
|
|
JP6746776B2 |
This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
|
|
JP6735321B2 |
The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chem...
|
|
JP6712679B2 |
It is provided a plant disease controlling agent having low toxicity to human and animals and excellent handling safety, and showing excellent controlling effects on various plant diseases and high antibiotic action to plant disease germ...
|
|
JP2020073518A |
To provide molecules capable of regulating the activity of the osteoprotegerin ligand (OPGL) used in combination with anti-resorptive agents such as bisphosphonates and selective estrogen receptor modifiers in treating osteopenic disorde...
|
|
JP6676650B2 |
The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using ...
|
|
JP6670846B2 |
A method of stabilizing riboflavin by affixing the riboflavin to at least one substrate for the riboflavin by covalent bonding, hydrogen bonding, Van der Waals forces, or a combination thereof, to form an optically-activated complex, is ...
|
|
JP6653663B2 |
The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic cation and of an organic active ingredient anion and also, optionally, of an organic fluorescent dye anion.
|
|
JP6636031B2 |
and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and meth...
|
|
JP2019214563A |
To provide molecules that can regulate the activity of the osteoprotegerin ligand (OPGL) in osteoclastogenesis.Antibodies that interact with the OPGL are disclosed. Methods of treating osteopenic disorders by administering a pharmaceutic...
|
|
JP6617104B2 |
The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chem...
|
|
JP6612882B2 |
The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor ...
|
|
JP6604938B2 |
The present invention provides haloalkane substrates, and linkers for connecting such substrates to functional elements (e.g., tags, labels, surfaces, etc.). Substrates and linkers described herein find use, for example, in labeling, det...
|
|
JP2019528080A |
The present invention relates to a method for easy and accurate identification of cancer cells in tissue samples such as surgical fields. In particular, compositions and methods use conjugates that include a profluorescent fluorescein-ba...
|
|
JP2019510006A |
The compounds of formula (I) [A, R, W, Q, n and m have the meaning according to the claims. ] Can be used specifically for the treatment of tauopathy and Alzheimer's disease. [Chemical 1]
|
|
JP6463855B2 |
The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORy and the treatment of diseases related to the modulation of RORy. The present invention ...
|
|
JP6458023B2 |
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
|
|
JP2018203749A |
To provide compositions for treatment and prevention of diseases caused by RNA- or DNA-containing viruses, and concomitant diseases.A pharmaceutical composition comprises a compound having the structure in the figure or a pharmaceuticall...
|
|
JP6417403B2 |
The present invention provides for compounds of formula I as acetyl-CoA carboxylase (ACC) inhibitors. The ACC inhibitors are useful for the prevention or treatment of metabolic syndrome, including obesity, dyslipidemia and hyperlipidemia...
|
